Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-O-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg: Randomized, double-blind, placebo-controlled, crossover study in healthy subjects

Drugs in R and D

Volumn 9, Issue 6, 2008, Pages 435-446

  Vaz Da Silva, Manuel ^a   Loureiro, Ana I ^a   Nunes, Teresa ^a   Lopes, Carlos ^a   Rocha, José ^a   MacHado, Rita ^a   Costa, Raquel ^a   Torrão, Leonel ^a   Falcão, Amílcar ^b   Wright, Lyndon ^a   Almeida, Luis ^a   Soares Da Silva, Patrício ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b Biocant   (Portugal)

Author keywords

Catechol O methyltransferase inhibitors, drug interactions; Decarboxylase inhibitors, drug interactions; Drug interactions; Levodopa carbidopa, drug interactions; Nebicapone, drug interactions; Pharmacokinetics; Research and development

Indexed keywords

3 O METHYLDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; NEBICAPONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CROSS REACTIVITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDICATION; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; VOMITING;

ACETOPHENONES; ADULT; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; LEVODOPA; MALE; TIME FACTORS; TYROSINE; YOUNG ADULT;

EID: 55749092627     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/0126839-200809060-00006     Document Type: Article

References (27)

1. Morgan JC, Sethi KD. Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs 2006; 11: 403-17
2. Rajput A, Rajput AH. Parkinson's disease management strategies. Expert Rev Neurother 2006; 6: 91-9
3. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease. Neurology 1984; 34: 991-6
4. Quinn N, Critchley P, Parkeds D, et al. When should levodopa be started? Lancet 1984; II: 985-6
5. Poewe W. The role of COMT inhibition in the treatment of Parkinson's disease. Neurology 2004; 62: S31-8
6. Dingemanse J. Issues important for rational COMT inhibition. Neurology 2000; 55: S24-7
7. Palma PN, Bonifacio MJ, Almeida L, et al. Restoring dopamine levels. In: Smith HJ, Simons C, Sewell RDE, editors. Protein misfolding in neurodegenerative diseases. Boca Raton (FL): CRC Press, 2008: 415-45
8. Lang AE, Lees A. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17: S45-51
9. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis [research letter]. Lancet 1998; 352: 958
10. Benabou R, Waters C. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Expert Opin Drug Saf 2003; 2: 263-7
11. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 2004; 62: S39-46
12. Bonifacio MJ, Vieira-Coelho MA, Soares-da-Silva P. Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. Eur J Pharmacol 2003; 460: 163-70
13. Parada A, Loureiro AI, Vieira-Coelho MA, et al. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. Eur J Pharmacol 2001; 420: 27-32
14. Almeida L, Vaz-da-Silva M, Silveira P, et al. Pharmacokinetic- pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin Neuropharmacol 2004; 27: 17-24
15. Parada A, Soares-Da-Silva P. BIA 3-202, a novel catechol-O- methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain. Pharmacology 2003; 68: 29-37
16. Silveira P, Vaz-Da-Silva M, Almeida L, et al. Pharmacokinetic- pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol 2003; 59: 603-9
17. Almeida L, Soares-da-Silva P. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs R D 2003; 4: 207-17
18. Almeida L, Soares-da-Silva P. Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. J Clin Pharmacol 2003; 43: 1350-60
19. Loureiro AI, Bonifacio MJ, Fernandes-Lopes C, et al. Human metabolism of nebicapone (BIA 3-202), a novel catechol-O-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos 2006; 34: 1856-62
20. Almeida L, Falcao A, Vaz-da-Silva M, et al. Effect of single-doses of nebicapone (BIA 3-202) on the catechol-O-methyltransferase (COMT) activity in healthy subjects [abstract]. Mov Disord 2006; 21: S641
21. Ferreira J, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 2008; 31: 2-18
22. Vieira-Coelho MA, Soares-da-Silva P. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 1996; 117: 516-20
23. Vieira-Coelho MA, Soares-da-Silva P. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 1999; 821: 69-78
24. Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol 2005; 28: 115-9
25. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa carbidopa in volunteers. Clin Neuropharmacol 1995; 18: 46-57
26. Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 1998; 245: 223-30
27. Ferreira JJ, Rascol O, Poewe W, et al. A double-blind, randomised, placebo-controlled trial to investigate the efficacy and safety of nebicapone in levodopa-treated Parkinson's disease patients with motor fluctuations [abstract]. Movement Disor ders 2008; 23 (Suppl. 1): S195